Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01865747 · ClinicalTrials.gov registry record · Phase 3
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
A Phase 3 study of Renal Cell Carcinoma, sponsored by Exelixis.
- Completed
- Registry status
- Phase 3
- Development phase
- 658
- Enrollment target
- 20
- Study locations
NCT01865747 is a Phase 3 study of Renal Cell Carcinoma that has completed, run by Exelixis. The registered enrollment target is 658 participants, above the 238-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (176% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT01865747, a Phase 3 study of Renal Cell Carcinoma, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 658 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.
Conditions Studied
Interventions
- DRUG Cabozantinib tablets
- DRUG Everolimus (Afinitor) tablets
Study Locations (20)
California
- - Duarte
- - La Jolla
- - Los Angeles
- - Los Angeles
- - Vallejo
Florida
- - Boca Raton
- - Miami
- - Miami
- - Orlando
- - Tampa
Arizona
- - Gilbert
- - Scottsdale
- - Tucson
Colorado
- - Aurora
- - Denver
Alabama
- - Birmingham
Alaska
- - Anchorage
Connecticut
- - New Haven
District of Columbia
- - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 658 participants |
| Start Date | 2013-06 |
| Est. Completion | 2021-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01865747
The ClinicalTrials.gov registry entry for NCT01865747 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 658 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 238-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (176% higher). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cabozantinib tablets is the first listed.
NCT01865747 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01865747 about?
NCT01865747 is a clinical study titled "A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma". The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.
What is the current status of trial NCT01865747?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 658 participants. The study started on 2013-06. Estimated completion is 2021-01-15.
What conditions does trial NCT01865747 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT01865747?
The interventions under investigation include: Cabozantinib tablets (DRUG), Everolimus (Afinitor) tablets (DRUG).
Who is sponsoring clinical trial NCT01865747?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01865747 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
RECRUITING · Phase 3
-
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.